Lifecare AS
OSE:LIFE
Lifecare AS
Lifecare AS engages in the research, testing, and development of medical sensors for health monitoring. The company is headquartered in Bergen, Hordaland. The company went IPO on 2018-07-10. Lifecare's activities are concentrated on the development of sensor for use as a medical product, initially the sensor Sencell for continuous monitoring of glucose (blood sugar) for people with diabetes. The technology is suitable for detecting and measuring a wide range of molecules that can occur in the human body, based on variations in osmotic pressure.
Lifecare AS engages in the research, testing, and development of medical sensors for health monitoring. The company is headquartered in Bergen, Hordaland. The company went IPO on 2018-07-10. Lifecare's activities are concentrated on the development of sensor for use as a medical product, initially the sensor Sencell for continuous monitoring of glucose (blood sugar) for people with diabetes. The technology is suitable for detecting and measuring a wide range of molecules that can occur in the human body, based on variations in osmotic pressure.
Strong funding secured: Lifecare raised NOK 80 million in Q3 and has arranged bridge financing through January 2026, supporting ongoing development and regulatory milestones.
Product progress: The company finalized the design and production setup for its implantable CGM, with a veterinary market launch targeted for early 2026 and a human launch aimed for 2027.
Clinical milestones: The first-in-human trial is awaiting regulatory approval, expected by the end of December, with study initiation planned for Q1 2026.
High operating expenses: Q3 operating costs reached NOK 66.4 million due to intensive product development and regulatory activities, resulting in an operating loss of NOK 65.9 million.
Planned rights issue: A rights issue of up to NOK 100 million is expected in January 2026, with NOK 80 million already underwritten, extending the cash runway into Q2 2026.
Veterinary study impact: The timing and confidence in the veterinary market launch depends partly on results from ongoing longevity studies in animals.
